Charles River Laboratories has launched its triple-immunodeficient mouse model, known as the NCG model. The NCG model is the first CRISPR-generated immunodeficient model offered by the company, and was developed by altering the Prkdc and Il2rg genes. “The launch of Charles River’s NCG model provides a significant opportunity to assist our clients in the development of life-saving, translational therapies,” said Dr. Iva Morse, corporate vice president, chief scientific officer, Global Researc...